Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TV-301
- Development stage
- Preclinical
- Lead developer
- TheraVac Biologics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
TV-301 is a virus-like particle (VLP)-based vaccine being developed by TheraVac Biologics for the treatment of neurodegenerative diseases, specifically Alzheimer's disease (prodromal to mild) and traumatic brain injury. As an active immunotherapy, it is designed to induce an immune response against the NLRP3 inflammasome components NLRP3 and ASC (Apoptosis-associated speck-like protein containing a CARD). By targeting these proteins, the vaccine aims to mitigate chronic neuroinflammation, a key driver of neurodegeneration. The VLP platform utilizes immunogenic peptides displayed on the particle surface to stimulate a robust immune response without the need for external adjuvants. TV-301 is currently in IND-enabling stages for Alzheimer's disease and preclinical development for traumatic brain injury.
02
Targets
PYCARD (Apoptosis-associated speck-like protein containing a CARD)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)
Beyond the preview
Go deeper on TV-301.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TV-301.